13FPulse
TX

TXG 10X GENOMICS INC-CLASS A

2026Q2 · CUSIP 88025U109 · Sector: Healthcare & Biotech

Piling in

Net holder growth ranks near the top of the market

Funds that own it
379
Institutions that reported holding it to the SEC
Net increase in holders
+53
Last quarter 326 → now 379
How unusual is that
Top 5%
Stronger buying than 95% of US stocks
What the filings say, in one paragraph

379 funds held TXG at the end of 2026Q2, up 53 from the quarter before. That is stronger buying than 95.1% of US stocks — among the most piled-into names this quarter. On the business itself, revenue over the last 12 months was $617M(YoY -4.3%), return on equity is -9.1%. TXG has had 11 buying rushes in its history, and the price moved +5.9% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2019Q4: holders=84 2020Q1: holders=102 2020Q2: holders=144 2020Q3: holders=216 2020Q4: holders=304 2021Q1: holders=321 2021Q2: holders=337 2021Q3: holders=330 2021Q4: holders=363 2022Q1: holders=311 2022Q2: holders=250 2022Q3: holders=230 2022Q4: holders=266 2023Q1: holders=253 2023Q2: holders=269 2023Q3: holders=254 2023Q4: holders=272 2024Q1: holders=284 2024Q2: holders=259 2024Q3: holders=264 2024Q4: holders=272 2025Q1: holders=273 2025Q2: holders=296 2025Q3: holders=316 2025Q4: holders=320 2026Q1: holders=326 2026Q2: holders=379 -88 -44 +0 +44 +88 75237398 19Q420Q321Q222Q122Q423Q324Q225Q125Q426Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 11 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2026Q2 Top 5%
2025Q3 Top 20% +16.7% +22.2%
2025Q2 Top 20% -8.5% +18.1%
2023Q2 Top 20% -15.4% -16.7%
2022Q4 Top 20% +5.0% +7.0%
2021Q4 Top 20% -13.2% -50.2%
2021Q2 Top 20% -8.9% +1.8%
2020Q4 Top 10% +2.3% -19.0%

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
167
Change in large funds
+19
Total value they hold
$4.9B
Funds buying for the first time
97
Funds that sold out entirely
44
Price change that quarter
+186.9%
Funds holding puts (bearish)
4
Funds holding calls (bullish)
5

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)
EPS (TTM)
$-0.59
EPS YoY
Revenue (TTM)
$0.6B
Revenue YoY
-4.3%
Net margin
-12.2%
ROE
-9.1%
Debt ratio
19.9%
FCF (TTM)
$121M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS
2021-09-30: EPS -0.15 2021-12-31: EPS -0.17 2022-03-31: EPS -0.38 2022-06-30: EPS -0.57 2022-09-30: EPS -0.37 2022-12-31: EPS -0.14 2023-03-31: EPS -0.44 2023-06-30: EPS -0.53 2023-09-30: EPS -0.79 2023-12-31: EPS -0.42 2024-03-31: EPS -0.50 2024-06-30: EPS -0.32 2024-09-30: EPS -0.30 2024-12-31: EPS -0.40 2025-03-31: EPS -0.28 2025-06-30: EPS 0.28 2025-09-30: EPS -0.22 2025-12-31: EPS -0.13 2026-03-31: EPS -0.10 2026-06-30: EPS -0.14 0M 92M 184M $M -0.87 -0.28 0.31 20182019202020212022202320242025202606/26 Revenue EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

Quarterly free cash flow
-152M-54M43M 201820192020202120222023202420252026
Latest quarter $25M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.